• Walk in for M.Pharm/M.Sc for HIV project at Alagappa University

    Advertisement for the post of JRF in DBT project Walk in Interview Applications are invited from eligible candidates for the appointment of JRF in DBT project titled as “In Silico screening, Theoretical Calculation and In vitro studies for the development of potential HIV-1 PR inhibitors”

  • ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS): A REVIEW

    { DOWNLOAD AS PDF }

    ABOUT AUTHOR
    Dr. (Mrs.) Anita Singh
    Department of Home Science,
    Kr. R.C.M. P.G College Mainpuri, U.P, India
    dranitasinghkrcm@gmail.com

    ABSTRACT
    Human immunodeficiency virus (HIV) is a lent virus (slowly-replicating retrovirus) that causes acquired immunodeficiency syndrome (AIDs). Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV enters macrophages and CD4+ T cells by the adsorption of glycoproteins on its surface to receptors on the target cell followed by fusion of the viral envelope with the cell membrane and the release of the HIV capsid into the cell. There is no cure for HIV/AIDS, but a variety of drugs can be used in combination to control the virus.

    [adsense:336x280:8701650588]

  • Gilead Sciences, Inc.  announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. Descovy is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. Descovy is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.

  • A new technique developed by a team of chemists at Stanford University has shown promise to be thousands of times more sensitive than current techniques to diagnose diseases whether it is a cancer or a virus like HIV.

  • ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced it has agreed to purchase Bristol-Myers Squibb’s late stage HIV R&D assets. In a separate deal, ViiV Healthcare has agreed to acquire Bristol-Myers Squibb’s HIV portfolio of pre-clinical and discovery stage research assets. Each deal is subject to clearance by the regulatory authorities and is expected to complete in early 2016.

Subscribe to HIV